Compare Medtronic PLC (MDT) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Xylem, Inc. — how do they compare? Medtronic PLC trades at $82.54 (market cap $106.61B), while Xylem, Inc. trades at $118.44 (market cap $28.67B). The key difference: Medtronic PLC is far larger — about 3.7× Xylem, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | XYL | |
|---|---|---|
Market Cap | $106.61B | $28.67B |
Sector | Health | Industrials |
52-Week High | $105.35 | $152.95 |
52-Week Low | $73.75 | $106.34 |
Enterprise Value | $125.36B | $29.92B |
Dividend Yield | 3.46% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Xylem (XYL) trades at $120.64, down 1.74% over 24 hours, with a bullish technical signal from moving averages and strong support near $118. The company reported consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding the $1.08 estimate, and revenue growth from $5.5B in 2022 to $9.04B in 2025. Recent developments include a partnership with Gross-Wen Technologies and leadership appointments, reinforcing its position in water solutions.
Outlook remains positive with a consensus price target of $153, implying 27% upside, though risks include execution of growth initiatives and macroeconomic pressures on industrial demand. The stock offers a dividend yield supported by 16 consecutive years of increases, appealing for long-term investors seeking water infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
